论文部分内容阅读
目的通过分析接受肿瘤细胞减灭术的临床Ⅲ期卵巢上皮性癌患者的手术切净与基本切净的５年存活率，探讨残余肿瘤的大小对其预后的影响。方法自１９８２年１月至１９９５年６月，共收治临床Ⅲ期卵巢上皮癌１８６例，对其进行回顾性研究，并对结果进行统计学处理。结果４３例肿瘤切除干净者，其５年存活率为３２５％；７６例肿瘤基本切净者的５年存活率为２１４％（Ｐ＜００１）。基本切净者，３２例术后１年内化疗≥６疗程的５年存活率为２５２％，４４例术后１年内化疗＜６疗程的５年存活率为２０１％。结论肿瘤切净者的５年存活率高于肿瘤基本切净者的５年存活率。术后１年内化疗≥６疗程可提高基本切净者的５年存活率。
Objective To investigate the effect of residual tumor size on the prognosis of patients with stage Ⅲ epithelial ovarian cancer who underwent cytoreductive surgery. Methods From January 1982 to June 1995, a total of 186 patients with clinical stage Ⅲ ovarian epithelial cancer were enrolled in this study. The data were retrospectively analyzed and the results were statistically analyzed. Results The 43-year survival rate was 32.5%. The 5-year survival rate of 76 patients with primary tumor was 21.4% (P <001). In the primary cutters, the 5-year survival rate of 32 patients with ≥6 courses of chemotherapy within 1 year after operation was 252%. The 5-year survival rate of 44 patients with less than 6 courses of chemotherapy within 1 year after operation was 201%. Conclusions The 5-year survival rate of tumor-cutters is higher than the 5-year survival rate of tumor-based cutters. Chemotherapy within 1 year after surgery ≥ 6 cycles can improve the basic cut net 5-year survival rate.